Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1991 May;82(5):613-20.
doi: 10.1111/j.1349-7006.1991.tb01894.x.

A cooperative randomized study on tegafur plus mitomycin C versus combined tegafur and uracil plus mitomycin C in the treatment of advanced gastric cancer

Affiliations
Clinical Trial

A cooperative randomized study on tegafur plus mitomycin C versus combined tegafur and uracil plus mitomycin C in the treatment of advanced gastric cancer

M Kurihara et al. Jpn J Cancer Res. 1991 May.

Abstract

A randomized controlled trial involving 13 institutions in Japan was conducted in order to compare the efficacy of tegafur plus mitomycin C (MMC) (Regimen A) and UFT (a combination of uracil and tegafur at a molar ratio of 4 to 1) plus MMC (Regimen B) for patients with advanced gastric cancer, who had not received any prior cancer chemotherapy. Regimen A (tegafur + MMC) consisted of 5 mg of MMC/m2/week given intravenously, and 500 mg of tegafur/m2/day given orally. Regimen B consisted of the same schedule of MMC and 375 mg of UFT/m2/day given orally. One hundred and eighty-six patients with primary gastric cancer were entered; 183 were eligible and 3 were ineligible for the study. A total of 169 were evaluable for efficacy of the treatment, including 90 patients with Regimen A and 79 with Regimen B. A response rate of 7.8% (7/90 cases) for Regimen A and one of 25.3% (20/79 cases) for Regimen B were obtained, indicating a significantly higher response rate for Regimen B according to the Criteria for Evaluating Efficacy of Chemotherapy/Radiation Therapy in the Treatment of Gastric Cancer (P = 0.004). Regarding side effects, no marked differences in either severity or incidence were observed between the two groups. The group assigned to Regimen B showed a significant survival advantage after adjustment for major prognostic factors using a proportional hazards model (P = 0.0398). Moreover, a close correlation of antitumor effect and survival duration was found when the above criteria were used.

PubMed Disclaimer

References

    1. ) Fujii , S. , Ikenaka , K. , Fukushima , M. and Shirasaka , T.Effect of uracil and its derivatives on antitumor activity of 5 ‐fluorouracil and 1‐(2‐tetrahydrofuryl)‐5‐fluorouracil . Gann , 69 , 763 – 772 ( 1978. ). - PubMed
    1. ) Fujii , S. , Kitano , S. , Ikenaka , K. and Shirasaka , T.Effect of coadministration of uracil or cytosine on the antitumor activity of clinical doses of 1‐ (2 ‐tetrahydrofuryl)‐ 5 ‐fluorouracil and level of 5‐fluorouracil in rodents . Gann , 70 , 209 – 214 ( 1979. ). - PubMed
    1. ) Ogawa , M.An overview of chemotherapy for advanced gastric cancer . In“Diagnosis and Treatment of Upper Gastrointestinal Tumors ”, ed. Friedman M. , Ogawa M. and Kisner D. , pp. 357 – 369 ( 1981. ). Excerpta Medica; , Amsterdam .
    1. ) Kurihara , M. , Shirakabe , H. , Izumi , T. , Miyasaka , K. , Maruyama , T. , Sasaki , Y. , Kobayashi , S. and Kamano , T.X‐ray and endoscopy in the evaluation of gastric cancer chemotherapy . In “ Diagnosis and Treatment of Upper Gastrointestinal Tumors ”, ed. Friedman M. , Ogawa M. and Kisner D. , pp. 428 – 449 ( 1981. ). Excerpta Medica; , Amsterdam .
    1. ) Suga , S. , Kimura , K. , Yoshida , Y. , Horiuchi , T. and Yokoyama , Y.UFTM chemotherapy for gastric cancer: effectiveness and comparison of survival between UFTM and surgical treatment in patients with Borrmann type 4 gastric cancer . In “ Fluoropyrimidines in Cancer Therapy ”, ed. Kimura K. , Fujii S. , Ogawa M. , Bodey G. B. and Alberto P. , pp. 311 – 319 ( 1984. ). Excerpta Medica; , Amsterdam .

Publication types

LinkOut - more resources